A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471
Study Identifier:
ACH471-205
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Danicopan
Date
Jun 2018 - Mar 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 12+ years
Requirements Information
Sex
Female & Male
Age
12+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Danicopan
Date
Jun 2018 - Mar 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 12+ years years
Requirements Information
Protocol Summary
The primary purpose of this study was to evaluate the efficacy of 12 months of oral ACH-0144471 (also known as danicopan and ALXN2040) in participants with C3G or IC-MPGN based on histologic scoring and proteinuria.
Trial Locations
Location
Status
Location
Clinical Study Site
Birmingham, Alabama, United States, 35294
Status
N/A
Location
Clinical Study Site
Stanford, California, United States, 94305
Status
N/A
Location
Clinical Study Site
New Haven, Connecticut, United States, 06511
Status
N/A
Location
Clinical Study Site
Cincinnati, Ohio, United States, 45221
Status
N/A
Location
Clinical Study Site
Columbus, Ohio, United States, 43210
Status
N/A
Location
Clinical Study Site
Philadelphia, Pennsylvania, United States, 19104
Status
N/A